Sign inJoin waitlistJoin the waitlist

Carl Allen

, Co-Director of the · Baylor College of Medicine

Credentials: · · ·

History

the · Baylor College of Medicine
Present
Pediatrics · Baylor College of Medicine
Present
Department of Pediatrics · Baylor College of Medicine
Present

Columbus Hospital Program
Pediatrics
Nationwide Children's Hospital
Ohio State University
Baylor College of Medicine

Research

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Review · Blood · 2016 · 1,128 citations
How I treat hemophagocytic lymphohistiocytosis
Review · Blood · 2011 · 867 citations
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Pediatric Blood & Cancer · 2008 · First of 4 authors · 476 citations

Kenneth McClain
72 papers
Olive Eckstein
27 papers · 9 as a fellow
Nader El-Mallawany
24 papers · 20 as a resident
Michael Jordan
17 papers
Nmazuo Ozuah
17 papers
Michelle Hermiston
16 papers
Joseph Lubega
14 papers
Casey McAtee
13 papers · 11 as a resident
Jennifer Picarsic
13 papers
Donald Parsons
12 papers
NG
Nitya Gulati
12 papers
DZ
Daniel Zinn
11 papers · 5 as a fellow

Grants

Characterization of Germline and Somatic Genetic Variants in Langerhans Cell Histiocytosis Pathogenesis
National Cancer Institute · R03
PI · $321K · Baylor College of Medicine
2026–2028
Pediatric Oncology Clinical Research Training Program
National Cancer Institute · K12
Contact PI · $3.6M · Baylor College of Medicine
2002–2027
Defining Pathogenic Mechanisms and Therapeutic Opportunities for Langerhans Cell Histiocytosis
National Cancer Institute · R01
PI · $5.3M · Icahn School of Medicine at Mount Sinai
2011–2026
Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for Sub-Saharan Africa (PARCA)
National Cancer Institute · U54
Contact PI · $5.7M · Baylor College of Medicine
2020–2026

Clinical trials

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2028
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2017–2024
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
Principal investigator · Completed · Early phase 1
Baylor College of Medicine
2013–2016
Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A
Principal investigator · Completed · Phase 2
Baylor College of Medicine
2012–2019